VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
TRDA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
TRDAEntrada Therapeutics, Inc.
$5.03$195M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksTRDAQuarterly Financials

Entrada Therapeutics, Inc. (TRDA) Quarterly Income Statement

120+ quarters historyFree accessUpdated daily

Entrada Therapeutics, Inc. (TRDA) quarterly income statement — complete revenue, gross profit & net income history

Income StatementBalance SheetCash FlowRatios

TRDA Income Statement

Quarterly statement

TRDA Income Statement

Entrada Therapeutics, Inc. (TRDA) annual income statement — 7-year revenue, gross profit & net income history

AnnualQuarterly
MetricQ3'26Q2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24Q2'24Q1'24Q4'23Q3'23Q2'23Q1'23Q4'22Q3'22Q2'22Q1'22Q4'21
Sales/Revenue905K898K875K1.3M1.61M1.95M20.56M37.4M19.57M94.69M59.12M41.85M43.73M18.17M25.26M00000
Revenue Growth %-43.93%-53.95%-95.74%-96.53%-91.75%-97.94%-65.23%-10.63%-55.25%421.16%134.05%---------
Cost of Goods Sold00805K886K38.36M000000022.19M26.3M23.1M00000
COGS % of Revenue--92%68.21%2376.77%-------50.74%144.74%91.46%-----
Gross Profit905K898K70K413K-36.75M1.95M20.56M37.4M19.57M94.69M59.12M41.85M21.54M-8.13M2.16M00000
Gross Margin %100%100%8%31.79%-2276.77%100%100%100%100%100%100%100%49.26%-44.74%8.54%-----
Gross Profit Growth %102.46%-53.95%-99.66%-98.9%-287.77%-97.94%-65.23%-10.63%-9.16%1264.75%2639.57%---------
Operating Expenses42.59M45.86M42.37M42.62M10.3M48.8M42.35M43.27M41.23M41.27M38.01M36.94M7.53M8.17M7.94M25.58M25.94M23.58M22.15M18.46M
OpEx % of Revenue4706.52%5107.02%4842.63%3281.06%638.41%2502.51%205.99%115.69%210.67%43.58%64.29%88.28%17.22%44.96%31.43%-----
Selling, General & Admin10.22M10.49M10.12M9.55M10.3M10.92M10.27M9.86M9.97M9.24M9.4M8.65M7.53M8.17M7.94M9.89M6.98M7.33M6.43M6.1M
SG&A % of Revenue1129.83%1168.37%1157.03%735.18%638.41%560.1%49.98%26.36%50.95%9.75%15.9%20.67%17.22%44.96%31.43%-----
Research & Development32.37M35.37M33.05M33.96M38.36M37.88M32.07M33.41M31.26M32.03M28.61M28.29M22.19M26.3M23.1M15.69M18.96M16.25M15.72M12.36M
R&D % of Revenue3576.69%3938.64%3777.6%2614.09%2376.77%1942.41%156.02%89.33%159.72%33.83%48.39%67.6%50.74%144.74%91.46%-----
Other Operating Expenses00-805K-886K-1000K0000000-1000K-1000K-1000K00000
Operating Income-41.69M-44.96M-42.3M-42.21M-47.05M-46.85M-21.79M-5.87M-21.66M53.42M21.11M4.91M14.01M-16.3M-5.78M-25.58M-25.94M-23.58M-22.15M-18.46M
Operating Margin %-4606.52%-5007.02%-4834.63%-3249.27%-2915.18%-2402.51%-105.99%-15.69%-110.67%56.42%35.71%11.72%32.04%-89.7%-22.88%-----
Operating Income Growth %11.4%4.03%-94.14%-619.41%-117.25%-187.69%-203.21%-219.61%-254.57%427.77%465.28%119.18%154.03%30.88%73.91%-38.56%-80.56%-137.96%-163.92%-113.34%
EBITDA-39.72M-44.12M-41.5M-44.99M-45.82M-45.81M-20.84M-4.88M-20.72M54.33M22.05M5.64M14.85M-15.57M-5.24M-25.05M-25.42M-23.12M-21.76M-18.1M
EBITDA Margin %-4388.4%-4913.36%-4742.63%-3463.66%-2838.97%-2349.49%-101.39%-13.04%-105.88%57.38%37.29%13.48%33.95%-85.69%-20.74%-----
EBITDA Growth %13.33%3.7%-99.09%-822.93%-121.13%-184.32%-194.54%-186.42%-239.57%448.98%520.82%122.52%158.4%32.66%75.92%-38.45%-80.77%-139.38%-165.57%-111.53%
D&A (Non-Cash Add-back)0841K805K-2.79M1.23M1.03M946K992K937K910K934K736K834K730K541K525K516K463K390K364K
EBIT-39.72M-42.73M-39.68M-39.07M-43.48M-42.92M-17.35M-739K-15.89M57.79M25.33M4.91M14.01M-16.3M-5.78M-25.58M-25.94M-23.58M-22.15M-18.46M
Net Interest Income1.97M2.23M2.62M3.14M3.57M3.92M4.44M5.13M5.77M4.37M4.21M4.29M4.05M4.22M2.66M0799K403K480K13K
Interest Income1.97M2.23M2.62M3.14M3.57M3.92M4.44M5.13M5.77M4.37M4.21M4.29M4.05M4.22M2.66M0799K403K480K13K
Interest Expense00000000000000000000
Other Income/Expense1.97M2.23M2.62M3.14M3.57M3.92M4.44M5.13M5.77M4.37M4.21M4.29M38.85M4.22M2.66M950K799K403K480K13K
Pretax Income-39.72M-42.73M-39.68M-39.07M-43.48M-42.92M-17.35M-739K-15.89M57.79M25.33M9.2M52.86M-12.08M-3.12M-24.63M-25.14M-23.18M-21.67M-18.45M
Pretax Margin %-4388.4%-4758.13%-4534.74%-3007.85%-2693.93%-2201.28%-84.39%-1.98%-81.21%61.03%42.84%21.98%120.86%-66.49%-12.36%-----
Income Tax27K35K38K92K654K178K0-1.87M-1.86M2.76M1.83M18.74M17.4M13.85M3.55M00000
Effective Tax Rate %-0.07%-0.08%-0.1%-0.24%-1.5%-0.41%0%253.04%11.7%4.77%7.23%203.77%32.91%-114.62%-113.7%0%0%0%0%0%
Net Income-39.74M-42.76M-39.72M-39.16M-44.13M-43.1M-17.35M1.13M-14.03M55.03M23.5M-9.54M35.46M-25.93M-6.67M-24.63M-25.14M-23.18M-21.67M-18.45M
Net Margin %-4391.38%-4762.03%-4539.09%-3014.93%-2734.45%-2210.41%-84.39%3.02%-71.7%58.11%39.74%-22.81%81.08%-142.7%-26.42%-----
Net Income Growth %9.95%0.79%-128.93%-3562.78%-214.52%-178.32%-173.84%111.85%-139.57%312.25%452.05%61.25%241.07%-11.86%69.2%-33.51%-74.2%-134.11%-158.6%-112.69%
Net Income (Continuing)-39.74M-42.76M-39.72M-39.16M-44.13M-43.1M-17.35M1.13M-14.03M55.03M23.5M-9.54M35.46M-25.93M-6.67M-24.63M-25.14M-23.18M-21.67M-18.45M
Discontinued Operations00000000000000000000
Minority Interest00000000000000000000
EPS (Diluted)-0.94-1.01-0.95-0.95-1.06-1.04-0.420.03-0.351.550.68-0.291.02-0.78-0.21-0.71-0.75-0.72-0.66-0.89
EPS Growth %11.32%2.88%-126.19%-3712.17%-202.86%-167.1%-161.76%109.07%-134.31%298.72%423.81%59.15%236%-8.33%68.18%20.22%-47.06%-50%-60.98%-111.9%
EPS (Basic)-0.94-1.01-0.95-0.95-1.06-1.04-0.420.03-0.351.610.70-0.291.07-0.78-0.21-0.71-0.75-0.72-0.66-0.89
Diluted Shares Outstanding42.37M42.22M41.84M41.37M41.46M41.34M41.07M43.05M40.63M35.51M34.79M33.37M34.78M33.16M32.37M31.35M31.3M31.28M31.25M20.78M
Basic Shares Outstanding42.37M42.22M41.84M41.37M41.46M41.34M41.07M40.84M40.63M34.18M33.5M33.37M33.28M33.16M32.37M31.35M31.3M31.28M31.25M20.78M
Dividend Payout Ratio--------------------